Research programme: GPR 119 agonists - Boehringer Ingelheim/Neurocrine Biosciences

Drug Profile

Research programme: GPR 119 agonists - Boehringer Ingelheim/Neurocrine Biosciences

Latest Information Update: 22 Feb 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim; Neurocrine Biosciences
  • Class Small molecules
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Type 2 diabetes mellitus

Most Recent Events

  • 22 Feb 2011 Early research is ongoing in USA
  • 18 Jun 2010 Early research in Type-2 diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top